EP Patent

EP2848242A1 — Orally disintegrating formulations of Linagliptin

Assigned to Sanovel Ilac Sanayi ve Ticaret AS · Expires 2015-03-18 · 11y expired

What this patent protects

The present invention relates to orally disintegrating formulations comprising linagliptin or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.

USPTO Abstract

The present invention relates to orally disintegrating formulations comprising linagliptin or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.

Drugs covered by this patent

Patent Metadata

Patent number
EP2848242A1
Jurisdiction
EP
Classification
—
Expires
2015-03-18
Drug substance claim
No
Drug product claim
No
Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.